Dr. Barth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
593 Eddy St
Providence, RI 02903Phone+1 401-444-5435Fax+1 401-793-2855
Education & Training
- Temple University HospitalResidency, Internal Medicine, 2012 - 2015
- Lewis Katz School of Medicine at Temple UniversityClass of 2012
Certifications & Licensure
- RI State Medical License 2015 - 2026
- PA State Medical License 2012 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response Start of enrollment: 2016 Jul 12
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citationsIxazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.Ari Pelcovits, Peter Barth, John L Reagan, Adam J Olszewski, Vallerie Rosati
The Oncologist. 2023-05-08 - 1 citationsMonoclonal Gammopathies in a Fracture Liaison Service.Brittany McCall, Zainab Ibrahim, Peter Barth, Roy K Aaron
Rhode Island Medical Journal. 2022-10-03 - 32 citationsSeroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.Thomas A Ollila, Rebecca H Masel, John L Reagan, Shaolei Lu, Ralph D Rogers
Cancer. 2022-09-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: